NASDAQ:VOR
Vor Biopharma Inc.
Vor Biopharma Inc. reported net income of −$696.0M in fiscal 2025. Free cash flow was −$143.7M, and the diluted share count rose 187.3%.Summary generated from Vor Biopharma Inc.'s SEC filings. Latest annual report filed Mar 30, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equityn/a
Debt / equityn/a
Free cash flow−$143.7M
FCF marginn/a
Share count change+187.3%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −69 | −93 | −126 | −121 | −372 |
| Net income | −69 | −92 | −118 | −117 | −696 |
| Free cash flow | −73 | −94 | −101 | −100 | −144 |
Recent filings
- 4Insider transaction report
Oct 5, 2026 - 4Insider transaction report
Aug 26, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 11, 2026 - 8-KDirector or officer change
Jul 7, 2026 - 8-KResults of a shareholder vote
Jun 12, 2026 - 8-KRegulation FD disclosure
Jun 8, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 13, 2026 - DEF 14AProxy statement
Apr 27, 2026